Oramed Pharmaceuticals (NASDAQ:ORMP) COO Joshua Hexter Sells 137,000 Shares of Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 137,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total value of $611,020.00. Following the completion of the sale, the chief operating officer directly owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Oramed Pharmaceuticals Stock Down 0.2%

Oramed Pharmaceuticals stock traded down $0.01 during mid-day trading on Thursday, hitting $4.60. 360,793 shares of the company were exchanged, compared to its average volume of 241,456. The business has a fifty day moving average of $4.08 and a 200 day moving average of $3.62. Oramed Pharmaceuticals Inc. has a 1-year low of $1.98 and a 1-year high of $5.19. The company has a market capitalization of $188.26 million, a PE ratio of 1.78 and a beta of 1.21.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Large investors have recently made changes to their positions in the company. SB Capital Management Inc acquired a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $5,415,000. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth approximately $738,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after buying an additional 7,738 shares during the last quarter. Ritholtz Wealth Management bought a new stake in shares of Oramed Pharmaceuticals during the first quarter worth approximately $529,000. Finally, Bank of America Corp DE lifted its holdings in Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 6,261 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.